

**Detection Rates, Pre-Test Carrier Risks, and Post-Test Residual Risks (Sorted by Gene)**

The detection rates and risks set forth below were derived using publicly available information, including gnomAD (<https://gnomad.broadinstitute.org>) and ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar>), and the rates were extrapolated using appropriate scientific methodologies. Published studies were used to derive individual carrier risks for CYP21A2, HBA1/HBA2 and SMN1. As additional clinical evidence is available, the data in these charts may be updated from time to time. These data are provided for general informational purposes only and are not intended as a substitute for professional medical judgment or medical advice.

For unknown or mixed ethnicity, consider using the ethnic background with the most conservative risk estimates.

N/A= Not Available

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>KCNJ1</b>	Bartter syndrome	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	1 in 426	1 in 43,000	1 in 170,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	1 in 205	1 in 20,000	1 in 80,000
		Other (population not assigned)	99	1 in 178	1 in 18,000	1 in 72,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>KCTD7</b>	Neuronal ceroid-lipofuscinosis	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>KIF14</b>	Joubert syndrome and related disorders, including Meckel-Gruber syndrome	African/African American	98	1 in 420	1 in 21,000	1 in 84,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	97	1 in 371	1 in 12,000	1 in 48,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>L1CAM</b>	L1 syndrome	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>LAMA2</b>	Muscular dystrophy, LAMA2-related	African/African American	99	1 in 249	1 in 25,000	1 in 100,000
		Latino/Admixed American	97	1 in 133	1 in 4,400	1 in 18,000
		Ashkenazi Jewish	99	1 in 296	1 in 30,000	1 in 120,000
		East Asian	99	1 in 345	1 in 34,000	1 in 140,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	1 in 206	1 in 10,000	1 in 40,000
		South Asian	98	1 in 325	1 in 16,000	1 in 64,000
		Other (population not assigned)	99	1 in 414	1 in 41,000	1 in 160,000
		US general population	98	1 in 197	1 in 9,800	1 in 39,000
<b>LAMA3</b>	Junctional epidermolysis bullosa	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>LAMB3</b>	Junctional epidermolysis bullosa	African/African American	98	1 in 311	1 in 16,000	1 in 64,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	99	1 in 243	1 in 24,000	1 in 96,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 312	1 in 31,000	1 in 120,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>LAMC2</b>	Junctional epidermolysis bullosa	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>LAMP2</b>	Danon disease	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>LARS1</b>	Acute infantile liver failure	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	1 in 481	1 in 48,000	1 in 190,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 472	1 in 47,000	1 in 190,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>LCA5</b>	Leber congenital amaurosis	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	1 in 219	1 in 22,000	1 in 88,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>LCK</b>	Severe combined immunodeficiency (SCID)	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
<b>LHX3</b>	Combined pituitary hormone deficiency	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>LIFR</b>	Stüve-Wiedemann syndrome	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>LIG4</b>	Severe combined immunodeficiency (SCID)	African/African American	97	1 in 253	1 in 8,400	1 in 34,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>LIPA</b>	Lysosomal acid lipase deficiency	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	1 in 327	1 in 33,000	1 in 130,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 232	1 in 23,000	1 in 92,000
		South Asian	99	1 in 450	1 in 45,000	1 in 180,000
		Other (population not assigned)	99	1 in 343	1 in 34,000	1 in 140,000
		US general population	99	1 in 285	1 in 28,000	1 in 110,000
<b>LIPN</b>	Autosomal recessive congenital ichthyosis (ARCI)	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>LMBRD1</b>	Methylmalonic acidemia with homocystinuria	African/African American	99	1 in 363	1 in 36,000	1 in 140,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	97	1 in 416	1 in 14,000	1 in 56,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	1 in 491	1 in 25,000	1 in 100,000
<b>LOXHD1</b>	Deafness and hearing loss, nonsyndromic	African/African American	98	1 in 314	1 in 16,000	1 in 64,000
		Latino/Admixed American	99	1 in 328	1 in 33,000	1 in 130,000
		Ashkenazi Jewish	99	1 in 130	1 in 13,000	1 in 52,000
		East Asian	99	1 in 339	1 in 34,000	1 in 140,000
		Finnish	99	1 in 301	1 in 30,000	1 in 120,000
		Non-Finnish European/Caucasian	99	1 in 152	1 in 15,000	1 in 60,000
		South Asian	99	1 in 334	1 in 33,000	1 in 130,000
		Other (population not assigned)	99	1 in 414	1 in 41,000	1 in 160,000
		US general population	99	1 in 191	1 in 19,000	1 in 76,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>LPL</b>	Lipoprotein lipase deficiency, familial	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 128	1 in 13,000	1 in 52,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>LRAT</b>	Leber congenital amaurosis	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>LRP2</b>	Donnai-Barrow syndrome	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>LRPPRC</b>	Leigh syndrome	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	1 in 326	1 in 16,000	1 in 64,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>LTBP4</b>	Cutis laxa	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>LYST</b>	Chediak-Higashi syndrome	African/African American	99	1 in 397	1 in 40,000	1 in 160,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>MAK</b>	Retinitis pigmentosa	African/African American	98	1 in 315	1 in 16,000	1 in 64,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>MALT1</b>	Severe combined immunodeficiency (SCID)	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>MAN2B1</b>	Alpha-mannosidosis	African/African American	99	1 in 287	1 in 29,000	1 in 120,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	1 in 206	1 in 21,000	1 in 84,000
		Non-Finnish European/Caucasian	99	1 in 426	1 in 43,000	1 in 170,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 494	1 in 49,000	1 in 200,000
<b>MANBA</b>	Beta-mannosidosis	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MCCC1</b>	3-Methylcrotonyl-CoA carboxylase deficiency	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	1 in 390	1 in 39,000	1 in 160,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 444	1 in 44,000	1 in 180,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 472	1 in 47,000	1 in 190,000
<b>MCCC2</b>	3-Methylcrotonyl-CoA carboxylase deficiency	African/African American	99	1 in 377	1 in 38,000	1 in 150,000
		Latino/Admixed American	99	1 in 123	1 in 12,000	1 in 48,000
		Ashkenazi Jewish	99	1 in 192	1 in 19,000	1 in 76,000
		East Asian	99	1 in 310	1 in 31,000	1 in 120,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 249	1 in 25,000	1 in 100,000
		South Asian	99	1 in 464	1 in 46,000	1 in 180,000
		Other (population not assigned)	99	1 in 168	1 in 17,000	1 in 68,000
		US general population	99	1 in 217	1 in 22,000	1 in 88,000



Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>MCEE</b>	Methylmalonic acidemia	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MCOLN1</b>	Mucopolipidosis type IV	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 118	1 in 12,000	1 in 48,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MCPH1</b>	Primary microcephaly	African/African American	98	1 in 488	1 in 24,000	1 in 96,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	1 in 241	1 in 24,000	1 in 96,000
		Finnish	97	1 in 202	1 in 6,700	1 in 27,000
		Non-Finnish European/Caucasian	99	1 in 416	1 in 42,000	1 in 170,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	1 in 401	1 in 20,000	1 in 80,000
		US general population	99	1 in 445	1 in 44,000	1 in 180,000
<b>MED17</b>	Microcephaly, postnatal progressive, with seizures and brain atrophy	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>MEFV</b>	Familial Mediterranean fever	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	1 in 116	1 in 12,000	1 in 48,000
		Ashkenazi Jewish	99	1 in 10	1 in 900	1 in 3,600
		East Asian	99	1 in 192	1 in 19,000	1 in 76,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 127	1 in 13,000	1 in 52,000
		South Asian	99	1 in 379	1 in 38,000	1 in 150,000
		Other (population not assigned)	99	1 in 56	1 in 5,500	1 in 22,000
		US general population	99	1 in 137	1 in 14,000	1 in 56,000
<b>MESP2</b>	Spondylothoracic dysostosis	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	1 in 124	1 in 4,100	1 in 16,000
		Non-Finnish European/Caucasian	97	1 in 233	1 in 7,700	1 in 31,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	97	1 in 48	1 in 1,600	1 in 6,400
		US general population	97	1 in 293	1 in 9,700	1 in 39,000
<b>MFSD8</b>	Neuronal ceroid-lipofuscinosis	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MID1</b>	Opitz G/BBB syndrome	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	98	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>MKKS</b>	Bardet-Biedl syndrome	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MKS1</b>	Ciliopathies	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	1 in 285	1 in 14,000	1 in 56,000
		Finnish	97	1 in 72	1 in 2,400	1 in 9,600
		Non-Finnish European/Caucasian	98	1 in 266	1 in 13,000	1 in 52,000
		South Asian	98	1 in 459	1 in 23,000	1 in 92,000
		Other (population not assigned)	97	1 in 232	1 in 7,700	1 in 31,000
		US general population	98	1 in 342	1 in 17,000	1 in 68,000
<b>MLC1</b>	Megalencephalic leukoencephalopathy with subcortical cysts type 1	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 192	1 in 19,000	1 in 76,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MMAA</b>	Methylmalonic acidemia	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>MMAB</b>	Methylmalonic acidemia	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	1 in 442	1 in 22,000	1 in 88,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MMACHC</b>	Methylmalonic acidemia with homocystinuria	African/African American	98	1 in 274	1 in 14,000	1 in 56,000
		Latino/Admixed American	98	1 in 83	1 in 4,100	1 in 16,000
		Ashkenazi Jewish	97	1 in 179	1 in 5,900	1 in 24,000
		East Asian	99	1 in 255	1 in 25,000	1 in 100,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	98	1 in 167	1 in 8,300	1 in 33,000
		South Asian	99	1 in 239	1 in 24,000	1 in 96,000
		Other (population not assigned)	98	1 in 162	1 in 8,100	1 in 32,000
		US general population	98	1 in 149	1 in 7,400	1 in 30,000
<b>MMADHC</b>	Methylmalonic acidemia with homocystinuria	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MMUT</b>	Methylmalonic acidemia	African/African American	99	1 in 170	1 in 17,000	1 in 68,000
		Latino/Admixed American	99	1 in 185	1 in 18,000	1 in 72,000
		Ashkenazi Jewish	99	1 in 316	1 in 32,000	1 in 130,000
		East Asian	99	1 in 116	1 in 12,000	1 in 48,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 329	1 in 33,000	1 in 130,000
		South Asian	99	1 in 239	1 in 24,000	1 in 96,000
		Other (population not assigned)	99	1 in 365	1 in 36,000	1 in 140,000
		US general population	99	1 in 248	1 in 25,000	1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>MOCS1</b>	Molybdenum cofactor deficiency	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MOCS2</b>	Molybdenum cofactor deficiency	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	1 in 451	1 in 15,000	1 in 60,000
		US general population	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
<b>MPI</b>	Congenital disorders of glycosylation	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	1 in 323	1 in 32,000	1 in 130,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MPL</b>	Congenital amegakaryocytic thrombocytopenia	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 59	1 in 5,800	1 in 23,000
		East Asian	99	1 in 294	1 in 29,000	1 in 120,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 278	1 in 28,000	1 in 110,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	1 in 301	1 in 30,000	1 in 120,000
		US general population	99	1 in 340	1 in 34,000	1 in 140,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>MPV17</b>	Mitochondrial DNA depletion syndrome, MPV17-related	African/African American	99	1 in 468	1 in 47,000	1 in 190,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MTHFD1</b>	Severe combined immunodeficiency (SCID)	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 464	1 in 46,000	1 in 180,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>MTM1</b>	Myotubular myopathy	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>MTRR</b>	Homocystinuria	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	97	1 in 467	1 in 16,000	1 in 64,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>MTTP</b>	Abetalipoproteinemia	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 187	1 in 19,000	1 in 76,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>MVK</b>	Mevalonate kinase deficiency	African/African American	99	1 in 332	1 in 33,000	1 in 130,000
		Latino/Admixed American	99	1 in 281	1 in 28,000	1 in 110,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	1 in 341	1 in 34,000	1 in 140,000
		Non-Finnish European/Caucasian	99	1 in 156	1 in 16,000	1 in 64,000
		South Asian	99	1 in 365	1 in 36,000	1 in 140,000
		Other (population not assigned)	99	1 in 254	1 in 25,000	1 in 100,000
		US general population	99	1 in 194	1 in 19,000	1 in 76,000
<b>MYO7A</b>	Usher syndrome (hearing loss and retinitis pigmentosa)	African/African American	99	1 in 169	1 in 17,000	1 in 68,000
		Latino/Admixed American	99	1 in 300	1 in 30,000	1 in 120,000
		Ashkenazi Jewish	99	1 in 380	1 in 38,000	1 in 150,000
		East Asian	99	1 in 297	1 in 30,000	1 in 120,000
		Finnish	97	1 in 319	1 in 11,000	1 in 44,000
		Non-Finnish European/Caucasian	99	1 in 158	1 in 16,000	1 in 64,000
		South Asian	99	1 in 215	1 in 21,000	1 in 84,000
		Other (population not assigned)	98	1 in 270	1 in 13,000	1 in 52,000
		US general population	99	1 in 181	1 in 18,000	1 in 72,000
<b>NAGA</b>	Schindler disease	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	1 in 410	1 in 41,000	1 in 160,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	1 in 349	1 in 35,000	1 in 140,000
		Non-Finnish European/Caucasian	99	1 in 115	1 in 11,000	1 in 44,000
		South Asian	99	1 in 165	1 in 16,000	1 in 64,000
		Other (population not assigned)	99	1 in 131	1 in 13,000	1 in 52,000
		US general population	99	1 in 160	1 in 16,000	1 in 64,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>NAGLU</b>	Mucopolysaccharidosis type III	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 466	1 in 47,000	1 in 190,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	99	1 in 344	1 in 34,000	1 in 140,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 425	1 in 42,000	1 in 170,000
<b>NAGS</b>	N-acetylglutamate synthetase deficiency	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>NBAS</b>	Acute infantile liver failure	African/African American	98	1 in 198	1 in 9,900	1 in 40,000
		Latino/Admixed American	98	1 in 228	1 in 11,000	1 in 44,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	1 in 212	1 in 21,000	1 in 84,000
		Finnish	98	1 in 244	1 in 12,000	1 in 48,000
		Non-Finnish European/Caucasian	99	1 in 105	1 in 10,000	1 in 40,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	1 in 118	1 in 5,900	1 in 24,000
		US general population	99	1 in 130	1 in 13,000	1 in 52,000
<b>NBN</b>	Nijmegen breakage syndrome	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	1 in 435	1 in 43,000	1 in 170,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	1 in 399	1 in 40,000	1 in 160,000
		Non-Finnish European/Caucasian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000



Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>NCF2</b>	Chronic granulomatous disease	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>NCF4</b>	Chronic granulomatous disease	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 491	1 in 49,000	1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>NDUFAF2</b>	Leigh syndrome	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>NDUFAF5</b>	Leigh syndrome	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 143	1 in 14,000	1 in 56,000
		East Asian	99	1 in 148	1 in 15,000	1 in 60,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	99	1 in 383	1 in 38,000	1 in 150,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 454	1 in 45,000	1 in 180,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
NDUFS4	Leigh syndrome	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
NDUFS6	Leigh syndrome	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
NDUFS7	Leigh syndrome	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
NDUFV1	Leigh syndrome	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	1 in 113	1 in 11,000	1 in 44,000
		Non-Finnish European/Caucasian	99	1 in 465	1 in 46,000	1 in 180,000
		South Asian	99	1 in 348	1 in 35,000	1 in 140,000
		Other (population not assigned)	99	1 in 402	1 in 40,000	1 in 160,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>NEB</b>	Nemaline myopathy	African/African American	93	1 in 125	1 in 1,800	1 in 7,200
		Latino/Admixed American	99	1 in 256	1 in 26,000	1 in 100,000
		Ashkenazi Jewish	99	1 in 304	1 in 30,000	1 in 120,000
		East Asian	98	1 in 273	1 in 14,000	1 in 56,000
		Finnish	99	1 in 139	1 in 14,000	1 in 56,000
		Non-Finnish European/Caucasian	92	1 in 137	1 in 1,700	1 in 6,800
		South Asian	98	1 in 234	1 in 12,000	1 in 48,000
		Other (population not assigned)	99	1 in 133	1 in 13,000	1 in 52,000
		US general population	99	1 in 152	1 in 15,000	1 in 60,000
<b>NEU1</b>	Sialidosis	African/African American	99	1 in 427	1 in 43,000	1 in 170,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	1 in 308	1 in 31,000	1 in 120,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>NGLY1</b>	Congenital disorder of deglycosylation	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	1 in 444	1 in 22,000	1 in 88,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>NHEJ1</b>	Severe combined immunodeficiency (SCID)	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>NIPAL4</b>	Autosomal recessive congenital ichthyosis (ARCI)	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 391	1 in 39,000	1 in 160,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>NONO</b>	Intellectual developmental disorder, NONO-related	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>NPC1</b>	Niemann-Pick disease type C	African/African American	99	1 in 421	1 in 42,000	1 in 170,000
		Latino/Admixed American	99	1 in 386	1 in 39,000	1 in 160,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	1 in 444	1 in 44,000	1 in 180,000
		Finnish	98	1 in 438	1 in 22,000	1 in 88,000
		Non-Finnish European/Caucasian	99	1 in 231	1 in 23,000	1 in 92,000
		South Asian	99	1 in 414	1 in 41,000	1 in 160,000
		Other (population not assigned)	99	1 in 359	1 in 36,000	1 in 140,000
		US general population	99	1 in 276	1 in 27,000	1 in 110,000
<b>NPC2</b>	Niemann-Pick disease type C	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>NPHP1</b>	Joubert syndrome and related disorders, including Meckel-Gruber syndrome	African/African American	99	1 in 365	1 in 36,000	1 in 140,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>NPHP3</b>	Joubert syndrome and related disorders, including Meckel-Gruber syndrome	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	1 in 232	1 in 23,000	1 in 92,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	1 in 303	1 in 15,000	1 in 60,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	98	1 in 419	1 in 21,000	1 in 84,000
		US general population	98	1 in 357	1 in 18,000	1 in 72,000
<b>NPHS1</b>	Nephrotic syndrome	African/African American	98	1 in 304	1 in 15,000	1 in 60,000
		Latino/Admixed American	99	1 in 398	1 in 40,000	1 in 160,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	1 in 38	1 in 1,200	1 in 4,800
		Non-Finnish European/Caucasian	99	1 in 206	1 in 21,000	1 in 84,000
		South Asian	98	1 in 355	1 in 18,000	1 in 72,000
		Other (population not assigned)	99	1 in 213	1 in 21,000	1 in 84,000
		US general population	99	1 in 245	1 in 24,000	1 in 96,000
<b>NPHS2</b>	Nephrotic syndrome	African/African American	99	1 in 489	1 in 49,000	1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 261	1 in 26,000	1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 386	1 in 39,000	1 in 160,000
		US general population	99	1 in 351	1 in 35,000	1 in 140,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>NR0B1</b>	Congenital adrenal hypoplasia, X-linked	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	97	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	97	N/A	N/A	N/A
<b>NTRK1</b>	Congenital insensitivity to pain with anhidrosis	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	1 in 343	1 in 34,000	1 in 140,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>OAT</b>	Gyrate atrophy of choroid and retina	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>OBSL1</b>	3M syndrome	African/African American	98	1 in 186	1 in 9,300	1 in 37,000
		Latino/Admixed American	99	1 in 332	1 in 33,000	1 in 130,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	97	1 in 220	1 in 7,300	1 in 29,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	98	1 in 209	1 in 10,000	1 in 40,000
		South Asian	97	1 in 299	1 in 9,900	1 in 40,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	1 in 226	1 in 11,000	1 in 44,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>OCA2</b>	Oculocutaneous albinism	African/African American	98	1 in 49	1 in 2,400	1 in 9,600
		Latino/Admixed American	99	1 in 153	1 in 15,000	1 in 60,000
		Ashkenazi Jewish	99	1 in 91	1 in 9,000	1 in 36,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	1 in 392	1 in 39,000	1 in 160,000
		Non-Finnish European/Caucasian	99	1 in 73	1 in 7,200	1 in 29,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 120	1 in 12,000	1 in 48,000
		US general population	99	1 in 80	1 in 7,900	1 in 32,000
<b>OCRL</b>	Dent disease	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>OPA3</b>	Costeff syndrome	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>OSTM1</b>	Osteopetrosis	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>OTC</b>	Ornithine transcarbamylase deficiency	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>OTOF</b>	Deafness and hearing loss, nonsyndromic	African/African American	99	1 in 269	1 in 27,000	1 in 110,000
		Latino/Admixed American	99	1 in 348	1 in 35,000	1 in 140,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 400	1 in 40,000	1 in 160,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 279	1 in 28,000	1 in 110,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 293	1 in 29,000	1 in 120,000
		US general population	99	1 in 295	1 in 29,000	1 in 120,000
<b>P3H1</b>	Osteogenesis imperfecta, autosomal recessive	African/African American	99	1 in 157	1 in 16,000	1 in 64,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PAH</b>	Phenylalanine hydroxylase deficiency, includes phenylketonuria (PKU)	African/African American	99	1 in 135	1 in 13,000	1 in 52,000
		Latino/Admixed American	99	1 in 74	1 in 7,300	1 in 29,000
		Ashkenazi Jewish	99	1 in 17	1 in 1,600	1 in 6,400
		East Asian	99	1 in 83	1 in 8,200	1 in 33,000
		Finnish	99	1 in 172	1 in 17,000	1 in 68,000
		Non-Finnish European/Caucasian	99	1 in 39	1 in 3,800	1 in 15,000
		South Asian	99	1 in 82	1 in 8,100	1 in 32,000
		Other (population not assigned)	99	1 in 41	1 in 4,000	1 in 16,000
		US general population	99	1 in 49	1 in 4,800	1 in 19,000



Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PANK2</b>	Pantothenate kinase-associated neurodegeneration	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	98	1 in 444	1 in 22,000	1 in 88,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	97	1 in 427	1 in 14,000	1 in 56,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PC</b>	Pyruvate carboxylase deficiency	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PCBD1</b>	Tetrahydrobiopterin deficiency	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 399	1 in 40,000	1 in 160,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PCCA</b>	Propionic acidemia	African/African American	99	1 in 494	1 in 49,000	1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PCCB</b>	Propionic acidemia	African/African American	97	1 in 274	1 in 9,100	1 in 36,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	1 in 265	1 in 26,000	1 in 100,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	1 in 488	1 in 24,000	1 in 96,000
<b>PCDH15</b>	Usher syndrome (hearing loss and retinitis pigmentosa)	African/African American	98	1 in 423	1 in 21,000	1 in 84,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	1 in 116	1 in 12,000	1 in 48,000
		East Asian	97	1 in 206	1 in 6,800	1 in 27,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	1 in 397	1 in 20,000	1 in 80,000
		South Asian	97	1 in 476	1 in 16,000	1 in 64,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	1 in 417	1 in 21,000	1 in 84,000
<b>PDHA1</b>	Pyruvate dehydrogenase deficiency	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	97	N/A	N/A	N/A
		Finnish	97	N/A	N/A	N/A
		Non-Finnish European/Caucasian	97	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	97	N/A	N/A	N/A
<b>PDHB</b>	Pyruvate dehydrogenase deficiency	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PDHX</b>	Pyruvate dehydrogenase deficiency	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PDP1</b>	Pyruvate dehydrogenase deficiency	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PEX1</b>	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	97	1 in 392	1 in 13,000	1 in 52,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	1 in 204	1 in 10,000	1 in 40,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	1 in 393	1 in 20,000	1 in 80,000
		US general population	98	1 in 266	1 in 13,000	1 in 52,000
<b>PEX2</b>	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	1 in 208	1 in 21,000	1 in 84,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
PEX3	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
PEX5	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
PEX6	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	1 in 470	1 in 23,000	1 in 92,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
PEX7	Rhizomelic chondrodysplasia punctata	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 429	1 in 43,000	1 in 170,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PEX10</b>	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PEX11B</b>	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PEX12</b>	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	98	1 in 437	1 in 22,000	1 in 88,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PEX13</b>	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
PEX14	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
PEX16	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
PEX19	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
PEX26	Zellweger spectrum disorder/ peroxisome biogenesis disorder	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PFKM</b>	Glycogen storage disease type VII	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	98	1 in 100	1 in 5,000	1 in 20,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PGM3</b>	Severe combined immunodeficiency (SCID)	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PHGDH</b>	Phosphoglycerate dehydrogenase deficiency	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	1 in 324	1 in 32,000	1 in 130,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PHKA1</b>	Glycogen storage disease type IX	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	98	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PHKA2</b>	Glycogen storage disease type IX	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>PHKB</b>	Glycogen storage disease type IX	African/African American	98	1 in 433	1 in 22,000	1 in 88,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 478	1 in 48,000	1 in 190,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 399	1 in 40,000	1 in 160,000
		South Asian	99	1 in 309	1 in 31,000	1 in 120,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 427	1 in 43,000	1 in 170,000
<b>PHKG2</b>	Glycogen storage disease type IX	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	97	1 in 356	1 in 12,000	1 in 48,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PKHD1</b>	Polycystic kidney disease, autosomal recessive	African/African American	99	1 in 153	1 in 15,000	1 in 60,000
		Latino/Admixed American	98	1 in 144	1 in 7,200	1 in 29,000
		Ashkenazi Jewish	97	1 in 62	1 in 2,000	1 in 8,000
		East Asian	99	1 in 184	1 in 18,000	1 in 72,000
		Finnish	99	1 in 38	1 in 3,700	1 in 15,000
		Non-Finnish European/Caucasian	99	1 in 92	1 in 9,100	1 in 36,000
		South Asian	99	1 in 187	1 in 19,000	1 in 76,000
		Other (population not assigned)	99	1 in 96	1 in 9,500	1 in 38,000
		US general population	99	1 in 107	1 in 11,000	1 in 44,000



Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PLA2G6</b>	Neurodegeneration with brain iron accumulation disorder	African/African American	99	1 in 303	1 in 30,000	1 in 120,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 255	1 in 25,000	1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 474	1 in 47,000	1 in 190,000
		South Asian	99	1 in 411	1 in 41,000	1 in 160,000
		Other (population not assigned)	98	1 in 403	1 in 20,000	1 in 80,000
		US general population	99	1 in 454	1 in 45,000	1 in 180,000
<b>PLEKHG5</b>	Distal spinal muscular atrophy	African/African American	97	1 in 76	1 in 2,500	1 in 10,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 428	1 in 43,000	1 in 170,000
		US general population	98	1 in 358	1 in 18,000	1 in 72,000
<b>PLOD2</b>	Osteogenesis imperfecta, autosomal recessive	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	1 in 261	1 in 26,000	1 in 100,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PLP1</b>	Pelizaeus-Merzbacher disease	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PM2</b>	Congenital disorders of glycosylation	African/African American	99	1 in 225	1 in 22,000	1 in 88,000
		Latino/Admixed American	99	1 in 116	1 in 12,000	1 in 48,000
		Ashkenazi Jewish	99	1 in 65	1 in 6,400	1 in 26,000
		East Asian	99	1 in 157	1 in 16,000	1 in 64,000
		Finnish	99	1 in 58	1 in 5,700	1 in 23,000
		Non-Finnish European/Caucasian	99	1 in 63	1 in 6,200	1 in 25,000
		South Asian	99	1 in 259	1 in 26,000	1 in 100,000
		Other (population not assigned)	99	1 in 81	1 in 8,000	1 in 32,000
		US general population	99	1 in 80	1 in 7,900	1 in 32,000
<b>PNP</b>	Severe combined immunodeficiency (SCID)	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PNPLA1</b>	Autosomal recessive congenital ichthyosis (ARCI)	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	1 in 492	1 in 49,000	1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PNPO</b>	Pyridoxal 5'-phosphate-dependent epilepsy	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>POLG</b>	POLG-related disorders	African/African American	99	1 in 144	1 in 14,000	1 in 56,000
		Latino/Admixed American	99	1 in 171	1 in 17,000	1 in 68,000
		Ashkenazi Jewish	99	1 in 115	1 in 11,000	1 in 44,000
		East Asian	99	1 in 53	1 in 5,200	1 in 21,000
		Finnish	99	1 in 62	1 in 6,100	1 in 24,000
		Non-Finnish European/Caucasian	99	1 in 49	1 in 4,800	1 in 19,000
		South Asian	99	1 in 255	1 in 25,000	1 in 100,000
		Other (population not assigned)	99	1 in 67	1 in 6,600	1 in 26,000
		US general population	99	1 in 64	1 in 6,300	1 in 25,000
<b>POLH</b>	Xeroderma pigmentosum	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	1 in 488	1 in 49,000	1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>POMGNT1</b>	Limb-girdle muscular dystrophy	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	1 in 202	1 in 20,000	1 in 80,000
		Non-Finnish European/Caucasian	99	1 in 313	1 in 31,000	1 in 120,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 414	1 in 41,000	1 in 160,000
<b>POMT1</b>	Limb-girdle muscular dystrophy	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	1 in 301	1 in 10,000	1 in 40,000
		East Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	1 in 449	1 in 22,000	1 in 88,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	98	1 in 458	1 in 23,000	1 in 92,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>POMT2</b>	Limb-girdle muscular dystrophy	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>POR</b>	Congenital adrenal hyperplasia	African/African American	98	1 in 450	1 in 22,000	1 in 88,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	1 in 273	1 in 14,000	1 in 56,000
		Non-Finnish European/Caucasian	99	1 in 312	1 in 31,000	1 in 120,000
		South Asian	98	1 in 456	1 in 23,000	1 in 92,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	1 in 370	1 in 37,000	1 in 150,000
<b>POU3F4</b>	Deafness and hearing loss, nonsyndromic	African/African American	99	N/A	N/A	N/A
		Latino/Admixed American	99	N/A	N/A	N/A
		Ashkenazi Jewish	99	N/A	N/A	N/A
		East Asian	99	N/A	N/A	N/A
		Finnish	99	N/A	N/A	N/A
		Non-Finnish European/Caucasian	99	N/A	N/A	N/A
		South Asian	99	N/A	N/A	N/A
		Other (population not assigned)	99	N/A	N/A	N/A
		US general population	99	N/A	N/A	N/A
<b>PPIB</b>	Osteogenesis imperfecta, autosomal recessive	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		US general population	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PPT1</b>	Neuronal ceroid-lipofuscinosis	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	1 in 74	1 in 7,300	1 in 29,000
		Non-Finnish European/Caucasian	99	1 in 304	1 in 30,000	1 in 120,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	1 in 190	1 in 19,000	1 in 76,000
		US general population	99	1 in 427	1 in 43,000	1 in 170,000
<b>PRCD</b>	Retinitis pigmentosa	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PRDM5</b>	Brittle cornea syndrome	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PRF1</b>	Familial hemophagocytic lymphohistiocytosis	African/African American	97	1 in 127	1 in 4,200	1 in 17,000
		Latino/Admixed American	99	1 in 373	1 in 37,000	1 in 150,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	1 in 499	1 in 50,000	1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	99	1 in 364	1 in 36,000	1 in 140,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	1 in 399	1 in 20,000	1 in 80,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PRKDC</b>	Severe combined immunodeficiency (SCID)	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PROP1</b>	Combined pituitary hormone deficiency	African/African American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PSAP</b>	Metachromatic leukodystrophy	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PTPRC</b>	Severe combined immunodeficiency (SCID)	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Other (population not assigned)	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>PTS</b>	Tetrahydrobiopterin deficiency	African/African American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 118	1 in 12,000	1 in 48,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PUS1</b>	Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Ashkenazi Jewish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Non-Finnish European/Caucasian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		South Asian	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	98	< 1 in 500	< 1 in 25,000	< 1 in 100,000
<b>PYCR1</b>	Cutis laxa	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	97	< 1 in 500	< 1 in 17,000	< 1 in 68,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
<b>PYGM</b>	Glycogen storage disease type V	African/African American	99	1 in 220	1 in 22,000	1 in 88,000
		Latino/Admixed American	99	1 in 157	1 in 16,000	1 in 64,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	1 in 491	1 in 49,000	1 in 200,000
		Finnish	99	1 in 496	1 in 50,000	1 in 200,000
		Non-Finnish European/Caucasian	99	1 in 128	1 in 13,000	1 in 52,000
		South Asian	98	1 in 490	1 in 24,000	1 in 96,000
		Other (population not assigned)	99	1 in 167	1 in 17,000	1 in 68,000
		US general population	99	1 in 147	1 in 15,000	1 in 60,000

Gene	Disorder	Ethnicity	Detection Rate (%)	Individual Carrier Risk	Individual Residual Risk After Negative Result	Risk of Affected Fetus When One Partner has a Carrier Result and One Partner has a Negative Result
<b>QDPR</b>	Tetrahydrobiopterin deficiency	African/African American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Latino/Admixed American	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Ashkenazi Jewish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		East Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Finnish	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Non-Finnish European/Caucasian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		South Asian	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		Other (population not assigned)	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000
		US general population	99	< 1 in 500	< 1 in 50,000	< 1 in 200,000